Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Denileukin Diftitox
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : AmerisourceBergen
Deal Size : Undisclosed
Deal Type : Agreement
Citius Expands Distribution Network for LYMPHIR with Cencora
Details : Under the agreement, Cencora will execute the distribution process of Lymphir (denileukin diftitox). It is being indicated for the treatemnt of Stage I-III cutaneous T-cell lymphoma.
Product Name : Lymphir
Product Type : Protein
Upfront Cash : Undisclosed
July 15, 2025
Lead Product(s) : Denileukin Diftitox
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : AmerisourceBergen
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Denileukin Diftitox
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : TenX Keane Acquisition
Deal Size : Undisclosed
Deal Type : Merger
Citius Completes Merger with TenX Keane to Form Citius Oncology, Inc.
Details : Lymphir (denileukin diftitox) is a specially engineered IL-2- diphtheria toxin fusion protein made using recombinant DNA technology for the treatment of cutaneous T-cell lymphoma.
Product Name : Lymphir
Product Type : Protein
Upfront Cash : Undisclosed
August 12, 2024
Lead Product(s) : Denileukin Diftitox
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : TenX Keane Acquisition
Deal Size : Undisclosed
Deal Type : Merger